Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: psoriasis

Can Peripheral Spondyloarthritis Be Reversed?

Ruth Jessen Hickman, MD  |  November 18, 2018

Currently, treatment options for patients with peripheral spondyloarthritis, which includes psoriatic arthritis and non-psoriatic types, are limited. Philippe Carron, MD, Department of Rheumatology, Ghent University Hospital, Belgium, says, “One of the problems we encounter in the daily management of peripheral spondyloarthritis is that we have no other therapeutic options in patients refractory to NSAIDs [non-steroidal…

Filed under:Axial SpondyloarthritisConditionsResearch Rheum Tagged with:TNF inhibitors

Walmart, Home Depot Adopt Health Insurer Tactic in Drug Copay Battle

Caroline Humer and Michael Erman  |  November 14, 2018

NEW YORK (Reuters)—Walmart and Home Depot, two of the top 10 U.S. employers, have embraced a health insurance strategy that punishes drugmakers for using discount cards to keep patients from switching or stopping their medications. Large U.S. companies have started tightly managing how employees and their family members use these popular discount, or copay, cards…

Filed under:Uncategorized Tagged with:copay accumulatorscopay cardscopay maximizersCVS Healthdiscount cardsExpress Scripts Holding Cohealth insurance strategyHome DepotWalmart

Ustekinumab May Be Effective for Lupus

Lara C. Pullen, PhD  |  November 12, 2018

New research underscores the possibility that interleukin (IL) 12, IL-23 or both play roles in the immunopathology of SLE. In the study, when added to standard-of-care treatment for active SLE, ustekinumab demonstrated better efficacy than placebo and had a safety profile consistent with that of ustekinumab therapy in other diseases…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:Lupussystemic lupus erythematosus (SLE)ustekinumab

Case Report: A Patient Presents with Rare, Fulminant SAPHO Syndrome

Ross J. Thibodaux, MD, & Nirupa J. Patel, MD  |  October 18, 2018

Synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome is a heterogeneous, inflammatory, musculoskeletal disease. The disease is an insidious, sterile osteitis with associated skin and synovial inflammation.1 Diagnosis can prove challenging, but a thorough clinical history, high clinical suspicion and imaging techniques can help clinch it. The below case reveals a rare, fulminant presentation of…

Filed under:Conditions Tagged with:case reportSAPHO Syndrome

Nivolumab-Induced Arthritis

Catherine Strahle, DO, Nathalie E. Chalhoub, MD, & Avis Ware, MD  |  October 18, 2018

Immune checkpoint inhibitors (ICIs) are increasingly used to treat a variety of malignancies, leading to better cancer treatment outcomes and patient survival. However, the emergence of autoimmunity has been a major adverse event resulting from ICI use. Below, we describe a patient who experienced a flare of preexisting psoriasis and new-onset severe psoriatic arthritis after…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:Cancercase reportimmune checkpoint inhibitor (ICI)nivolumabPsoriatic Arthritisskin psoriasis

Revised Application Expected for IV Meloxicam; Plus EU Approves Tildrakizumab

Michele B. Kaufman, PharmD, BCGP  |  October 9, 2018

After meeting with the FDA, the makers of intravenous meloxicam plan to resubmit the treatment’s new drug application…

Filed under:AnalgesicsConditionsDrug UpdatesPain Syndromes Tagged with:Chronic painEU approvalFDAmeloxicamPainplaque psoriasistildrakizumabU.S. Food and Drug Administration (FDA)

More Evidence TNF Inhibitors Raise Risk of Peripheral Neuropathy

Megan Brooks  |  October 8, 2018

NEW YORK (Reuters Health)—A large epidemiological study provides more evidence of a link between tumor necrosis factor inhibitors (TNFi) and peripheral neuropathy (PN). “These events are rare and the benefit of these drugs still outweigh this risk so this should not change practice,” cautions first author Dr. Mahyar Etminan from the University of British Columbia…

Filed under:Drug Updates Tagged with:Peripheral NeuropathyTNF inhibitorstumor necrosis factortumor necrosis factor (TNF) inhibitors

Celiac Awareness Makes a Difference for Rheumatology Patients

Carina Stanton  |  September 24, 2018

Celiac disease and gluten sensitivity are difficult to diagnose, but they affect multiple systems and are associated with other autoimmune diseases. Lan Chen, MD, PhD, believes better testing and clearer education will be a gamechanger for celiac patients…

Filed under:Conditions Tagged with:celiac diseaseDiagnosisgluten

California Insurance Commissioner Sues AbbVie over Humira

Natasha Yetman  |  September 23, 2018

(Reuters)—On Tuesday, Insurance Commissioner Dave Jones filed a complaint on behalf of the State of California against AbbVie Inc., alleging the drugmaker gave illegal kickbacks to healthcare providers to prescribe its blockbuster drug, Humira. The regulator alleged that AbbVie engaged in a far-reaching scheme including cash, meals, drinks, gifts, trips and patient referrals, as well…

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumabHumiralawsuitLegal

Case Report: A Psoriatic Arthritis Patient with Dactylitis & Enthesitis

Samantha C. Shapiro, MD; Jemima Albayda, MD; & Ana-Maria Orbai, MD, MHS  |  September 20, 2018

A 36-year-old woman presented at the Johns Hopkins Arthritis Center for a second opinion regarding a diagnosis of psoriatic arthritis (PsA). One year prior to our evaluation, she had developed pain and stiffness in her hands, feet, knees, ankles, elbows and shoulders. She had mild plaque psoriasis of the scalp and base of the neck,…

Filed under:ConditionsOther Rheumatic ConditionsPsoriatic Arthritis Tagged with:DactylitisEnthesitisPsAPsoriatic Arthritis

  • « Previous Page
  • 1
  • …
  • 27
  • 28
  • 29
  • 30
  • 31
  • …
  • 55
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences